Skip to main content
. Author manuscript; available in PMC: 2021 May 17.
Published in final edited form as: Cancer Chemother Pharmacol. 2019 May 17;84(2):359–371. doi: 10.1007/s00280-019-03863-w

Fig. 3.

Fig. 3

Concentration response curves in three representative NCI60 panel cell lines after compound exposure for 2 days (blue), 3 days (red), 7 days (yellow) or 11 days (green) for the histone deacetylase (HDAC) inhibitors belinostat, quisinostat, panobinostat, abexinostat, JNJ-16241199, and romidepsin